• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,026.17
  • -0.85 %
  • -$326.17
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
CRISPR Therapeutics AG (CRSP) Stock Price, News & Analysis

CRISPR Therapeutics AG (CRSP) Stock Price, News & Analysis

Currency in USD Disclaimer

$46.30

-$0.96

(-2.03%)

Day's range
$45.51
Day's range
$47.21
50-day range
$44.44
Day's range
$59.07
  • Country: CH
  • ISIN: CH0334081137
52 wk range
$43.42
Day's range
$91.1
  • CEO: Dr. Samarth Kulkarni Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 7.41
  • Piotroski Score 3.00
  • Grade Sector Perform
  • Symbol (CRSP)
  • Company CRISPR Therapeutics AG
  • Price $46.30
  • Changes Percentage (-2.03%)
  • Change -$0.96
  • Day Low $45.51
  • Day High $47.21
  • Year High $91.10

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 02/17/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $89.50
  • High Stock Price Target $180.00
  • Low Stock Price Target $52.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$2.70
  • Trailing P/E Ratio -21.43
  • Forward P/E Ratio -21.43
  • P/E Growth -21.43
  • Net Income $-153,610,000

Income Statement

Quarterly

Annual

Latest News of CRSP

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

CRISPR Therapeutics AG Frequently Asked Questions

  • What were the earnings of CRSP in the last quarter?

    In the last quarter CRISPR Therapeutics AG earnings were on Tuesday, November, 5th. The CRISPR Therapeutics AG maker reported -$1.01 EPS for the quarter, beating analysts' consensus estimates of -$1.33 by $0.32.

  • What is the CRISPR Therapeutics AG stock price today?

    Today's price of CRISPR Therapeutics AG is $46.30 — it has decreased by -2.03% in the past 24 hours. Watch CRISPR Therapeutics AG stock price performance more closely on the chart.

  • Does CRISPR Therapeutics AG release reports?

    Yes, you can track CRISPR Therapeutics AG's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the CRISPR Therapeutics AG stock forecast?

    Watch the CRISPR Therapeutics AG chart and read a more detailed CRISPR Therapeutics AG stock forecast to see what analysts suggest you do with its shares.

  • What is CRISPR Therapeutics AG stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NASDAQ, exchange stock trades by CRISPR Therapeutics AG stock ticker.

  • How to buy CRISPR Therapeutics AG stocks?

    Like other stocks, CRSP shares are sold on stock exchanges such as NASDAQ. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is CRISPR Therapeutics AG's EBITDA?

    CRISPR Therapeutics AG measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in CRISPR Therapeutics AG’s financial statements.

  • What is the CRISPR Therapeutics AG's net income ratio for the financial year 2023?

    The net income ratio for the financial year 2023 is -0.4138133543, which equates to approximately -41.38%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in CRISPR Therapeutics AG stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including CRISPR Therapeutics AG's financials relevant news, and technical analysis. CRISPR Therapeutics AG's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for CRISPR Therapeutics AG stock currently indicates a “sell” signal. For more insights, review CRISPR Therapeutics AG’s technical analysis.

  • A revenue figure for CRISPR Therapeutics AG for its last quarter?

    CRISPR Therapeutics AG published it's last quarterly revenues at $602,000.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.